TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01045174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nebulizer (breath-actuated versus conventional continuous-output)
Description: Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nebulizer (breath-actuated versus conventional continuous-output)
Description: Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
Study: NCT01734096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group
Study: NCT02299310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan 80mg/tablet, 1 tablet once daily (crossover)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: Perindopril 4mg/tablet, 1 tablet once daily (crossover)
Study: NCT04442893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rumination-Focused Cognitive Behaviour Therapy
Description: Rumination-Focused Cognitive Behavioural Therapy(RFCBT) is based on a differentiation between functional and dysfunctional styles of perseverative thinking with the helpful style characterized as a concrete, process-focused and specific style of thinking and the idea that rumination is a habit maintained by negative reinforcement. In line with the theoretical assumptions, RFCBT combines strategies from behavioral activation with strategies to foster concrete, process-focused and specific thinking.

Intervention type: OTHER
Group type: OTHER
Intervention: Health Education programme
Description: Health education programme would be any planned activity or set of activities aimed at increasing health literacy and developing life skills conducing to health (e.g. decision making, problem solving, critical thinking, interpersonal skills, stress management, coping with emotions).
Study: NCT02045784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.

Intervention type: OTHER
Group type: OTHER
Intervention: Breast milk
Description: Unlimited breast feeding
Study: NCT02512380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel;oxaliplatin;s1
Description: Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin;s1
Description: oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
Study: NCT04222192

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Epidural block
Description: Epidural catheter insertions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural block
Description: Epidural catheter insertions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural block
Description: Epidural catheter insertions
Study: NCT03988946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement via Transseptal Access
Description: The Cephea Transseptal Mitral Valve System is intended for use in symptomatic patients with moderate to severe degenerative or functional mitral regurgitation, who are poor candidates for surgery and who are anatomically eligible for the treatment.
Study: NCT01685814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide, Bortezomib
Description: Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
Study: NCT02336386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDD
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDD Plus Bortezomib
Description: Chemotherapy plus Proteasome Inhibitors
Study: NCT00763152

Intervention type: OTHER
Intervention: Observation of transponder stability
Description: Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
Study: NCT01685814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide, Bortezomib
Description: Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Bortezomib
Description: Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Bortezomib
Description: Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous stem cell transplant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous stem cell transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic stem cell transplant
Study: NCT03284346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo CARE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Undergo standard stretching program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Receive Polar heart rate monitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03587870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition with Fresubin Intensive
Description: Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral nutrition with Fresubin Intensive
Description: Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients
Study: NCT03989752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Robotic Exoskeleton for Ambulation
Description: 16-week walking program (34 sessions) with an overground walking robotic exoskeleton guided by a certified physical therapist
Study: NCT01873443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, MTX, folic acid
Description: Rituximab IV 1000mg MTX 10\~25mg/week Folic acid at least 5mg/week
Study: NCT02716194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX 826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX 826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX 826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octocog alfa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octocog alfa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octocog alfa
Study: NCT00716638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused Cognitive Behavior Therapy
Description: This intervention comprises 10 sessions of trauma-focused cognitive behavior therapy for PTSD with the components (a) prolonged imaginal exposure, (b) in vivo exposure, and (c) cognitive restructuring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: This intervention comprises 10 sessions of EMDR according to the standard protocol.
Study: NCT00361894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
Study: NCT00537264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-related quality of life assessment
Description: Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-related quality of life assessment
Description: Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
Study: NCT04733001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration
Study: NCT01193816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loxapine
Description: Each patient may receive a maximum dosage of 900mg of Loxapine per day (drinkable solution through gastric probe) or the same volume of placebo. 2 initial administrations of 150 mg followed by potential readministration of 100 mg of loxapine. Maximum duration of treatment will be 14 days.The dosage by day is defined by patients' clinical condition, assessed with RASS score.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01108562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
Study: NCT01376817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids
Description: 40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fat emulsion with MCT and LCT
Description: 40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
Study: NCT02717325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-08)
Study: NCT01108562

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.
Study: NCT01811381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
Study: NCT04324593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous analysis (PIVA) algorithm
Description: An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.
Study: NCT01598441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost nebuliser solution
Description: Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: distilled water
Description: 1-2 ml aerosolized distilled water inhalation per session
Study: NCT02145026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: Epoetin beta 30,000 or 60,000 IU per week SC injection
Study: NCT02541162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral information and interviews
Description: interviews about sexuality and self experience during the disease
Study: NCT04102813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Therapy
Description: It consists in a group of body-mind techniques based on functional theory developed in Italy by prof. Luciano Rispoli. These techniques are oriented to stimulate a diaphragmatic breathing though a thoracic and abdominal manipulation, with the aim to activate the parasympathetic nervous system and therefore reducing inflammation
Study: NCT01739621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 12 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 24 mg
Study: NCT02185313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual stimulus to follow
Study: NCT00103311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03480126

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Herbal Teas
Description: Steeped tea ingested 3 times a day for 3 mos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Teas
Description: Steeped tea ingested 3 times a day for 3 mos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Teas
Description: Steeped tea ingested 3 times a day for 3 mos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Teas
Description: Steeped tea ingested 3 times a day for 3 mos
Study: NCT02944370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlayFit - modified exercise games
Description: Play modified games with other adults three times a week for 12 weeks. Complete a brief survey on the games played and program satisfaction.
Study: NCT01802788

Intervention type: DEVICE
Intervention: St Jude Medical Portico replacement aortic valve

Intervention type: DEVICE
Intervention: St Jude Medical Portico replacement aortic valve

Intervention type: PROCEDURE
Intervention: Transcatheter Aortic Valve Implant

Intervention type: PROCEDURE
Intervention: Transcatheter Aortic Valve Implant
Study: NCT04229888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow
Description: Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Based (Sham) Treatment
Description: A light based (sham) treatment will be used to compare effectiveness to the LipiFlow treatment.
Study: NCT01646814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL2200
Description: PL2200, containing 325 mg aspirin active ingredient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablets
Description: 325 mg aspirin tablets (USP)
Study: NCT03522961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin Prophylaxis/Placebo
Description: Drug: Nitrofurantoin Drug: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry capsules
Description: Drug: TheraCran® One Cranberry capsules
Study: NCT00039013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT01501136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)
Description: DDP 20 mg/m2,ivgtt（intravenously guttae）, d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）
Description: DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gemcitabine,pegaspargase,cisplatin,dexamethasone
Description: Radiotherapy 50Gy is followed by chemotherapy(DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna
Description: Radiotherapy 50Gy is followed by chemotherapy(DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Suitable type intensity-modulated radiation therapy(IMRT)50Gy
Study: NCT01811381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic yoga
Description: Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic yoga
Description: Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic yoga
Description: Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: non aerobic yoga
Description: Subjects will take two non-aerobic (stretching) classes weekly as well as practice two 30 minutes yoga routines at home weekly.~Each week, subjects will attend two one hour non-aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute non-aerobic yoga practice sessions at home.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will take 4 capsules x BID of placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 4 capsules x BID of placebo
Study: NCT01332019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a
Description: Administered as specified in the treatment arm
Study: NCT02535078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp (IMCgp100)
Description: soluble gp100-specific T cell receptor with anti-CD3 scFV